
Opinion|Videos|July 18, 2024
TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations
Key opinion leaders examine TYK2 inhibition and deucravacitinib, focusing on the mechanism of action, safety profile, and strategies for effective patient-provider communication regarding this treatment approach.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Phase 2b Analysis Shows Consistent Vitiligo Repigmentation With Ritlecitinib
3
FAQtual Insights: Safe Approaches to Off Label Prescribing
4
Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata
5









